The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options
Open accessAbstract
Although Alzheimer's disease (AD) is the world's leading cause of dementia and the population of patients with AD continues to grow, no new therapies have been approved in more than a decade. Many clinical trials of single-agent therapies have failed to affect disease progression or symptoms compared with placebo. The complex pathophysiology of AD may necessitate combination treatments rather than monotherapy. The goal of this narrative literature review is to describe types of combination therapy, review the current clinical evidence for combination therapy regimens (both symptomatic and disease-modifying) in the treatment of AD, describe innovative clinical trial study designs that may be effective in testing combination therapy, and discuss the regulatory and drug development landscape for combination therapy. Successful combination therapies in other complex disorders, such as human immunodeficiency virus, may provide useful examples of a potential path forward for AD treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, these treatments, whose effectiveness is only partial and temporary at best, affect only the consequences of AD rather than the cause [1,17,157,158].”
From Alzheimer's Disease: Treatment Strategies and Their Limitations. (2022) · cites this paper as [157]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Neuroinflammation has been identified as a key contributor to the pathobiology of AD [2–4]”
From evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“One example of this is rasagiline, which combines neuroprotective and amyloid-processing properties with monoamine oxidase B inhibition [217].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [217]
The cited source says what the claim attributes to it.
In the citing paper
“As an illustration, ongoing clinical trials combine novel DMT- or symptomatic-based treatments with standard-of-care medications (such as memantine or cholinesterase inhibitors) [217,218,219].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [217]
In the citing paper
“Another type of combination therapy is represented by multifunctional compounds, which incorporate several activities or targets into a single medication.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [217]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744
Self-citationEpidemiology of Alzheimer disease
Reitz, C., Brayne, C., & Mayeux, R. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.2 · Cited by 1,675
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
The antioxidant properties of serum albumin
Roche, M., Rondeau, P., Singh, N. R., Tarnus, E., & Bourdon, E. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.04.057 · Cited by 1,255
Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease
Schneider, L. S., Tariot, P. N., Dagerman, K. S., Davis, S. M., Hsiao, J. K., Ismail, M. S., Lebowitz, B. D., Lyketsos, C. G., Ryan, J. M., Stroup, T. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061240 · Cited by 1,206
Tau pathology in Alzheimer disease and other tauopathies
Iqbal, K., del C. Alonso, A., Chen, S., Chohan, M. O., El-Akkad, E., Gong, C.-X., Khatoon, S., Li, B., Liu, F., Rahman, A., et al. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.09.008 · Cited by 1,037
Al-Atrache, Z., Cader, A., & Appelt, D. M. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.06.894 · Cited by 765
Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease
Egan, M. F., Kost, J., Tariot, P. N., Aisen, P. S., Cummings, J. L., Vellas, B., Sur, C., Mukai, Y., Voss, T., Furtek, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1706441 · Cited by 685
Self-citationTargeting the β secretase BACE1 for Alzheimer's disease therapy
Yan, R., & Vassar, R. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70276-x · Cited by 630
Antipsychotic Drug Use and Mortality in Older Adults with Dementia
Gill, S. S., Bronskill, S. E., Normand, S.-L. T., Anderson, G. M., Sykora, K., Lam, K., Bell, C. M., Lee, P. E., Fischer, H. D., Herrmann, N., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-11-200706050-00006 · Cited by 624
Cholinergic system during the progression of Alzheimer’s disease: therapeutic implications
Mufson, E. J., Counts, S. E., Perez, S. E., & Ginsberg, S. D. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.11.1703 · Cited by 587
Atypical antipsychotics for aggression and psychosis in Alzheimer's disease
Ballard, C. G., Waite, J., & Birks, J. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003476.pub2 · Cited by 525
Self-citationA Controlled, Randomized, Delayed-Start Study of Rasagiline in Early Parkinson Disease
(2004) · Archives of Neurology · doi:10.1001/archneur.61.4.561 · Cited by 485
Kennedy, M. E., Stamford, A. W., Chen, X., Cox, K., Cumming, J. N., Dockendorf, M. F., Egan, M., Ereshefsky, L., Hodgson, R. A., Hyde, L. A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad9704 · Cited by 428
Gauthier, S., Feldman, H. H., Schneider, L. S., Wilcock, G. K., Frisoni, G. B., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Wischik, D. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31275-2 · Cited by 427
Dextromethorphan Plus Ultra Low‐Dose Quinidine Reduces Pseudobulbar Affect
Pioro, E. P., Brooks, B. R., Cummings, J., Schiffer, R., Thisted, R. A., Wynn, D., Hepner, A., & Kaye, R. (2010) · Annals of Neurology · doi:10.1002/ana.22093 · Cited by 370
Self-citationYoudim, M. B. H., Gross, A., & Finberg, J. P. M. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703826 · Cited by 342
Bateman, R. J., Benzinger, T. L., Berry, S., Clifford, D. B., Duggan, C., Fagan, A. M., Fanning, K., Farlow, M. R., Hassenstab, J., McDade, E. M., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.07.005 · Cited by 303
Tau-aggregation inhibitor therapy for Alzheimer's disease
Wischik, C. M., Harrington, C. R., & Storey, J. M. D. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.008 · Cited by 262
5-HT6 Receptor Antagonists as Novel Cognitive Enhancing Agents for Alzheimer's Disease
Upton, N., Chuang, T. T., Hunter, A. J., & Virley, D. J. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.008 · Cited by 255
Evidence for Ordering of Alzheimer Disease Biomarkers
Jack, C. R. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.183 · Cited by 223
Evans, S. R. (2010) · Journal of Experimental Stroke and Translational Medicine · doi:10.6030/1939-067x-3.1.8 · Cited by 208
Ritchie, C. W., Molinuevo, J. L., Truyen, L., Satlin, A., Van der Geyten, S., & Lovestone, S. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00454-x · Cited by 202
Tau-Centric targets and drugs in clinical development for the treatment of alzheimer's disease
Panza, F., Solfrizzi, V., Seripa, D., Imbimbo, B. P., Lozupone, M., Santamato, A., Zecca, C., Barulli, M. R., Bellomo, A., Pilotto, A., et al. (2016) · BioMed Research International · doi:10.1155/2016/3245935 · Cited by 195
Combination Therapy in Alzheimer???s Disease: A Review of Current Evidence
Schmitt, B., Bernhardt, T., Moeller, H.-J., Heuser, I., & Fr??lich, L. (2004) · CNS Drugs · doi:10.2165/00023210-200418130-00001 · Cited by 182
Piette, F., Belmin, J., Vincent, H., Schmidt, N., Pariel, S., Verny, M., Marquis, C., Mely, J., Hugonot-Diener, L., Kinet, J.-P., et al. (2011) · Alzheimer's Research & Therapy · doi:10.1186/alzrt75 · Cited by 173
Fox, C., Crugel, M., Maidment, I., Auestad, B. H., Coulton, S., Treloar, A., Ballard, C., Boustani, M., Katona, C., & Livingston, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035185 · Cited by 173
Self-citationAlzPathway: a comprehensive map of signaling pathways of Alzheimer’s disease
Mizuno, S., Iijima, R., Ogishima, S., Kikuchi, M., Matsuoka, Y., Ghosh, S., Miyamoto, T., Miyashita, A., Kuwano, R., & Tanaka, H. (2012) · BMC Systems Biology · doi:10.1186/1752-0509-6-52 · Cited by 170
Atri, A., Frölich, L., Ballard, C., Tariot, P. N., Molinuevo, J. L., Boneva, N., Windfeld, K., Raket, L. L., & Cummings, J. L. (2018) · JAMA · doi:10.1001/jama.2017.20373 · Cited by 167
Self-citationRasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition
Youdim, M. B. H., Bar Am, O., Yogev‐Falach, M., Weinreb, O., Maruyama, W., Naoi, M., & Amit, T. (2005) · Journal of Neuroscience Research · doi:10.1002/jnr.20350 · Cited by 166
Wilkinson, D., Windfeld, K., & Colding-Jørgensen, E. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70198-x · Cited by 164
Youdim, M. B. H., & Weinstock, M. (2001) · Cellular and Molecular Neurobiology · doi:10.1023/a:1015131516649 · Cited by 164
Treatment Strategies Targeting Amyloid -Protein
Schenk, D., Basi, G. S., & Pangalos, M. N. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006387 · Cited by 153
DEFINING DISEASE MODIFYING THERAPY FOR ALZHEIMER’S DISEASE
Cummings, J., & Fox, N. (2017) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2017.12 · Cited by 139
Self-citationWang, A., Das, P., Switzer, R. C., Golde, T. E., & Jankowsky, J. L. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5077-10.2011 · Cited by 118
Ballard, C. G., & Waite, J. (2006) · Research Portal (King's College London) · Cited by 112
Self-citationIs RAGE Still A Therapeutic Target For Alzheimer’s Disease?
Deane, R. J. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.51 · Cited by 104
Genetic Heterogeneity in Alzheimer Disease and Implications for Treatment Strategies
Dominantly Inherited Alzheimer Network, Ringman, J. M., Goate, A., Masters, C. L., Cairns, N. J., Danek, A., Graff-Radford, N., Ghetti, B., & Morris, J. C. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0499-8 · Cited by 96
Henry, G., Williamson, D. E., & Tampi, R. R. (2011) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317511402051 · Cited by 94
Hori, Y., Takeda, S., Cho, H., Wegmann, S., Shoup, T. M., Takahashi, K., Irimia, D., Elmaleh, D. R., Hyman, B. T., & Hudry, E. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.586602 · Cited by 78
Pharmacologic Principles for Combination Therapy
Toews, M. L., & Bylund, D. B. (2005) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200504-037sr · Cited by 74
Layton, D., Harris, S., Wilton, L., & Shakir, S. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105056524 · Cited by 68
Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update
Wang, S., Han, C., Lee, S.-J., Jun, T., Patkar, A. A., Masand, P. S., & Pae, C. (2016) · Chonnam Medical Journal · doi:10.4068/cmj.2016.52.3.159 · Cited by 60
The Role of Mast Cells in Alzheimer’s Disease
Shaik, Y. B., & Conti, P. (2016) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/61914 · Cited by 58
Profile of gantenerumab and its potential in the treatment of Alzheimer's disease
Nisticò, R., Novakovic, D., Feligioni, M., Scaccianoce, S., Piccinin, S., Mercuri, N. B., Nicoletti, F., Caruso, A., Schepisi, C., & Errico, F. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s53401 · Cited by 51
Two randomized controlled trials of SB742457 in mild‐to‐moderate Alzheimer's disease
Maher‐Edwards, G., Watson, C. B., Ascher, J. A., Barnett, C., Boswell, D., Davies, J. T., Fernández, M., Kurz, A., Zanetti, O. O., Safirstein, B., et al. (2015) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2015.04.001 · Cited by 47
Challenges, solutions, and recommendations for Alzheimer's disease combination therapy
Hendrix, J. A., Bateman, R. J., Brashear, H. R., Duggan, C. D., Carrillo, M. C., Bain, L. J., Demattos, R. B., Katz, R. G., Ostrowitzki, S., Siemers, E., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.02.007 · Cited by 44
Boada, M., Ramos‐Fernández, E., Guivernau, B., Muñoz, F. J., Costa, M., Ortiz, A. M., Jorquera, J. I., Núñez, L., Torres, M., & Páez, A. (2014) · Neurología · doi:10.1016/j.nrl.2014.02.003 · Cited by 42
Boada, M., Ramos‐Fernández, E., Guivernau, B., Muñoz, F. J., Costa, M., Ortiz, A. M., Jorquera, J. I., Núñez, L., Torres, M., & Páez, A. (2016) · Neurología (English Edition) · doi:10.1016/j.nrleng.2014.02.009 · Cited by 34
Combination products: modernizing the regulatory paradigm
Hunter, N. L., & Sherman, R. E. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.66 · Cited by 25
Farias, S. T., Gauthier, S. G., Wimo, A. B., & Rosa‐Neto, P. (2015) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2015.85 · Cited by 24
Levodopa combined with peripheral decarboxylase inhibition in Parkinson's disease.
Barbeau, A., Mars, H., Botez, M. I., et al. (1972) · PubMed · Cited by 23
Fessel, W. J. (2017) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317517698790 · Cited by 21
Antipsychotic use in elderly patients with dementia: Efficacy and safety concerns
Marvanová, M. (2014) · Mental Health Clinician · doi:10.9740/mhc.n204371 · Cited by 7
I-SPY 2 Breast Cancer Trial as a Model for Innovation in Alzheimer Disease Therapies
Messmer, M. F., Wilhelm, E. E., & Shoulson, I. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.1528 · Cited by 6
Mackey, H. M., Cho, W., Ward, M. E., Fang, Y., Suliman, S., Ho, C., & Paul, R. H. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.06.1210 · Cited by 5
Research works printed but not linked: 1
- Cummings, 2008, Effect of cholinesterase inhibitors on behavior, Neurobiol Aging, 29, S6
Cited by
Clinical trials of new drugs for Alzheimer disease
Huang, L.-K., Chao, S.-P., & Hu, C.-J. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0609-7 · Cited by 702
“creases the level of aggregated tau proteins to alleviate tau-related neuronal damage [67].”
BackgroundAlzheimer's Disease: Treatment Strategies and Their Limitations.
Passeri, E., Elkhoury, K., Morsink, M., Broersen, K., Linder, M., Tamayol, A., Malaplate, C., Yen, F. T., & Arab-Tehrany, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213954 · Cited by 689
“However, these treatments, whose effectiveness is only partial and temporary at best, affect only the consequences of AD rather than the cause [1,17,157,158].”
BackgroundAlzheimer’s disease and its treatment by different approaches: A review
Srivastava, S., Ahmad, R., & Khare, S. K. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113320 · Cited by 467
Traumatic Brain Injury and Risk of Neurodegenerative Disorder
Brett, B. L., Gardner, R. C., Godbout, J., Dams-O’Connor, K., & Keene, C. D. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.05.025 · Cited by 430
Yiannopoulou, K. G., Anastasiou, A. I., Zachariou, V., & Pelidou, S.-H. (2019) · Biomedicines · doi:10.3390/biomedicines7040097 · Cited by 330
Metadata
- Authors
- Cummings, J. L., Tong, G., & Ballard, C.
- Affiliations
- Cleveland Clinic (US)
- Lundbeck (United States) (US)
- University of Exeter (GB)
- Corresponding author
- Cummings, Jeffrey L.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2019-02-12
- Volume
- 67
- Issue
- 3
- Pages
- 779-794
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC6398562
- OpenAlex
- W2913000824
- Cited by
- 588
- References
- 61
- Citations by year
- 2026: 45 · 2025: 92 · 2024: 90 · 2023: 113 · 2022: 110 · 2021: 81 · 2020: 42 · 2019: 13
- FWCI
- 7.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Digital Scholarship - UNLV (University of Nevada Reno) (submittedVersion, cc-by-nc)
- Royal Devon and Exeter Research Repository (Royal Devon and Exeter) (submittedVersion, cc-by-nc)
- Funders
- H. Lundbeck A/S (P20GM109025)
- National Institutes of Health
- National Institute of General Medical Sciences (P20GM109025)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, combination therapy
- MeSH terms
- Alzheimer Disease, Drug Therapy, Combination, Humans, Nootropic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.